Bretylium
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-(2-bromobenzyl)-N,N-dimethylethanaminium | |
| Clinical data | |
| MedlinePlus | a682861 |
| Pregnancy cat. | C (AU) C (US) |
| Legal status | ℞-only (US) |
| Routes | IV, IM |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | NA |
| Metabolism | None |
| Half-life | 7-8 hours |
| Excretion | Renal |
| Identifiers | |
| CAS number | 59-41-6  |
| ATC code | C01BD02 |
| PubChem | CID 2431 |
| DrugBank | DB01158 |
| ChemSpider | 2337 |
| UNII | RZR75EQ2KJ |
| KEGG | D00645  |
| ChEBI | CHEBI:3172 |
| ChEMBL | CHEMBL1199080 |
| Chemical data | |
| Formula | C11H17BrN+ |
| Mol. mass | 243.163 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Bretylium (also bretylium tosylate) is an antiarrhythmic agent.[1] It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5-10 mg/kg and side effects are hypertension followed by hypotension and ventricular ectopy.
It was patented in 1978 by Marvin Bacaner at the University of Minnesota.[2]
Uses[edit]
It is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. [3]
It is contraindicated in patients with AV (atrioventricular) heart block or digoxin toxicity.
Bretylium should be used only in an ICU or Emergency Department setting and should not be used elsewhere due to its dramatic actions and its predominant side effect of hypotension.
References[edit]
|
||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
